Wells Fargo
AUTL

Wells Fargo’s Autolus Therapeutics AUTL Stock Holding History

Wells Fargo’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$287K Buy
207,856
+10,773
+5% +$16.4K ﹤0.01% 4476
2025
Q4 		$392K Sell
197,083
-34,049
-15% -$52.3K ﹤0.01% 4655
2025
Q3 		$377K Sell
231,132
-21,970
-9% -$42.9K ﹤0.01% 4506
2025
Q2 		$577K Sell
253,102
-8,044
-3% -$13.3K ﹤0.01% 4035
2025
Q1 		$405K Sell
261,146
-5,169
-2% -$10.5K ﹤0.01% 4243
2024
Q4 		$626K Sell
266,315
-119,558
-31% -$404K ﹤0.01% 4035
2024
Q3 		$1.4M Buy
385,873
+5,567
+1% +$22.2K ﹤0.01% 3323
2024
Q2 		$1.32M Buy
380,306
+3,534
+0.9% +$15.3K ﹤0.01% 3297
2024
Q1 		$2.4M Sell
376,772
-30,678
-8% -$191K ﹤0.01% 2823
2023
Q4 		$2.62M Sell
407,450
-150,075
-27% -$572K ﹤0.01% 2691
2023
Q3 		$1.3M Buy
557,525
+38,083
+7% +$109K ﹤0.01% 3131
2023
Q2 		$1.24M Buy
519,442
+32,073
+7% +$76.1K ﹤0.01% 3307
2023
Q1 		$897K Buy
487,369
+111,708
+30% +$218K ﹤0.01% 3451
2022
Q4 		$714K Sell
375,661
-14,178
-4% -$35.9K ﹤0.01% 3432
2022
Q3 		$834K Buy
389,839
+25,884
+7% +$76.7K ﹤0.01% 3348
2022
Q2 		$1.03M Buy
363,955
+124,320
+52% +$378K ﹤0.01% 3275
2022
Q1 		$1M Buy
239,635
+40,462
+20% +$170K ﹤0.01% 3890
2021
Q4 		$1.03M Sell
199,173
-54,257
-21% -$326K ﹤0.01% 4077
2021
Q3 		$1.66M Buy
253,430
+110,426
+77% +$698K ﹤0.01% 3825
2021
Q2 		$950K Buy
143,004
+72,868
+104% +$452K ﹤0.01% 4242
2021
Q1 		$401K Buy
70,136
+43,361
+162% +$321K ﹤0.01% 4812
2020
Q4 		$239K Buy
26,775
+10,292
+62% +$110K ﹤0.01% 4986
2020
Q3 		$191K Buy
16,483
+4,007
+32% +$58.1K ﹤0.01% 4981
2020
Q2 		$200K Sell
12,476
-2,445
-16% -$27.1K ﹤0.01% 4910
2020
Q1 		$89K Buy
14,921
+13,119
+728% +$121K ﹤0.01% 5115
2019
Q4 		$24K Sell
1,802
-400
-18% -$5.24K ﹤0.01% 5702
2019
Q3 		$27K Buy
2,202
+1,502
+215% +$19.9K ﹤0.01% 5732
2019
Q2 		$11K Buy
700
+400
+133% +$8.95K ﹤0.01% 5895
2019
Q1 		$9K Sell
300
-250
-45% -$7.11K ﹤0.01% 5651
2018
Q4 		$18K Sell
550
-600
-52% -$19.7K ﹤0.01% 5799
2018
Q3 		$35K Buy
1,150
+900
+360% +$24.3K ﹤0.01% 5705
2018
Q2 		$7K Buy
+250
New +$6.61K ﹤0.01% 6022

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's AUTL Position: Q1 2026 in Review

Wells Fargo increased its Autolus Therapeutics (AUTL) stake by 5.5% in Q1 2026, buying an estimated $16.4K and bringing the position to 207,856 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #4476.

Wells Fargo first reported a position in AUTL in Q2 2018 and has held it in 32 quarters since. The position peaked at $2.62M in Q4 2023. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Wells Fargo held 207,856 shares of Autolus Therapeutics worth $287K as of Q1 2026.
  • Wells Fargo bought 10,773 Autolus Therapeutics shares in Q1 2026, an estimated $16.4K.
  • Autolus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4476 holding.
  • Wells Fargo first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Wells Fargo's Autolus Therapeutics position peaked at $2.62M in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.